STOCK TITAN

Leap Therapeutic SEC Filings

LPTX NASDAQ

Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Cypherpunk Technologies Inc. filings document the issuer's transition from Leap Therapeutics, its Zcash-focused digital asset treasury activity, and formal public-company reporting after the name change. Current reports cover financial results, ZEC purchases, material agreements, equity offering arrangements, capital-structure disclosures, and Nasdaq listing-compliance notices.

Proxy materials cover annual meeting voting and board governance for the renamed company. The filing record also preserves disclosure categories tied to the company's prior oncology identity, including corporate status, risk factors, financing arrangements, and governance matters connected to its continuing subsidiary-based therapeutic research operations.

Rhea-AI Summary

Cypherpunk Technologies Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for its common stock. Nasdaq notified the company on May 21, 2026 that it now meets Nasdaq Listing Rule 5550(a)(2), and Nasdaq considers the matter closed.

The company had previously received a deficiency letter on March 4, 2026 after its closing bid price stayed below $1.00 per share for 30 consecutive business days. Regaining compliance reduces the risk of delisting from The Nasdaq Capital Market for this specific rule.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Cypherpunk Technologies Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for its common stock. Nasdaq notified the company on May 21, 2026 that it now meets Nasdaq Listing Rule 5550(a)(2), and Nasdaq considers the matter closed.

The company had previously received a deficiency letter on March 4, 2026 after its closing bid price stayed below $1.00 per share for 30 consecutive business days. Regaining compliance reduces the risk of delisting from The Nasdaq Capital Market for this specific rule.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Cypherpunk Technologies reported a much larger net loss for the first quarter of 2026 as its Zcash-focused digital asset strategy faced a sharp price drop. Net loss was $77.2 million for the quarter ended March 31, 2026, compared with $15.4 million a year earlier, driven mainly by a $77.6 million unrealized loss on the fair value of its ZEC treasury holdings as ZEC fell from $508.09 to $240.47.

Operating expenses shifted significantly, with research and development dropping to $0.2 million from $12.9 million as clinical trials were completed, while general and administrative expenses rose to $4.7 million from $3.0 million due largely to RSU-based compensation. Cash and cash equivalents were $6.7 million on March 31, 2026, and ZEC treasury holdings classified as digital assets receivable were valued at $73.8 million based on the quarter-end ZEC price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Cypherpunk Technologies reported a much larger net loss for the first quarter of 2026 as its Zcash-focused digital asset strategy faced a sharp price drop. Net loss was $77.2 million for the quarter ended March 31, 2026, compared with $15.4 million a year earlier, driven mainly by a $77.6 million unrealized loss on the fair value of its ZEC treasury holdings as ZEC fell from $508.09 to $240.47.

Operating expenses shifted significantly, with research and development dropping to $0.2 million from $12.9 million as clinical trials were completed, while general and administrative expenses rose to $4.7 million from $3.0 million due largely to RSU-based compensation. Cash and cash equivalents were $6.7 million on March 31, 2026, and ZEC treasury holdings classified as digital assets receivable were valued at $73.8 million based on the quarter-end ZEC price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Cypherpunk Technologies Inc. reported a Q1 2026 net loss of $77.2M, driven mainly by a $77.6M unrealized loss on the change in fair value of an embedded derivative tied to its Zcash (ZEC) digital asset receivable. Operating expenses fell sharply as research and development dropped to $0.2M from $12.9M after winding down clinical programs, while general and administrative costs rose to $4.7M on higher stock-based compensation and professional fees. Cash and cash equivalents were $6.7M and ZEC holdings were valued at $73.8M as of March 31, 2026, with an accumulated deficit of $539.7M. Management believes existing liquidity plus capacity under a $200M at-the-market program is sufficient to fund operations for at least 12 months, though a previously identified material weakness in internal control over financial reporting remains unremediated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Summary

Cypherpunk Technologies Inc. reported a Q1 2026 net loss of $77.2M, driven mainly by a $77.6M unrealized loss on the change in fair value of an embedded derivative tied to its Zcash (ZEC) digital asset receivable. Operating expenses fell sharply as research and development dropped to $0.2M from $12.9M after winding down clinical programs, while general and administrative costs rose to $4.7M on higher stock-based compensation and professional fees. Cash and cash equivalents were $6.7M and ZEC holdings were valued at $73.8M as of March 31, 2026, with an accumulated deficit of $539.7M. Management believes existing liquidity plus capacity under a $200M at-the-market program is sufficient to fund operations for at least 12 months, though a previously identified material weakness in internal control over financial reporting remains unremediated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
Rhea-AI Summary

Cypherpunk Technologies Inc. is asking stockholders to vote at its all-virtual 2026 Annual Meeting on June 18, 2026. Holders of 97,678,728 shares of common stock as of April 29, 2026 may participate and vote online.

Investors are being asked to elect two Class III directors, Nissim Mashiach and Will McEvoy, to terms running through 2029, approve an advisory "Say-on-Pay" vote on executive compensation, and ratify EisnerAmper LLP as independent auditors for 2026. Several long-time directors, including Joseph Loscalzo, Christopher Mirabelli, James Cavanaugh and Richard Schilsky, will leave the board around the meeting, after which eight directors will remain.

The proxy details a virtual-only format with internet, telephone, mail and online meeting voting options, explains the company’s governance structure and committee independence, and outlines 2025 pay for key executives, including CEO Douglas Onsi and new Chief Investment Officer Will McEvoy, whose packages combine salary with significant equity-based awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
proxy
-
Rhea-AI Summary

Cypherpunk Technologies Inc. is asking stockholders to vote at its all-virtual 2026 Annual Meeting on June 18, 2026. Holders of 97,678,728 shares of common stock as of April 29, 2026 may participate and vote online.

Investors are being asked to elect two Class III directors, Nissim Mashiach and Will McEvoy, to terms running through 2029, approve an advisory "Say-on-Pay" vote on executive compensation, and ratify EisnerAmper LLP as independent auditors for 2026. Several long-time directors, including Joseph Loscalzo, Christopher Mirabelli, James Cavanaugh and Richard Schilsky, will leave the board around the meeting, after which eight directors will remain.

The proxy details a virtual-only format with internet, telephone, mail and online meeting voting options, explains the company’s governance structure and committee independence, and outlines 2025 pay for key executives, including CEO Douglas Onsi and new Chief Investment Officer Will McEvoy, whose packages combine salary with significant equity-based awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
proxy
-
Rhea-AI Summary

CYPHERPUNK TECHNOLOGIES INC. director Christopher Mirabelli reported an open-market sale of 60,000 shares of Common Stock at an average price of $0.7105 per share on March 26, 2026. According to the footnote, the sale was made to cover estimated taxes related to a previously reported settlement of RSUs on March 13, 2026. After this transaction, Mirabelli directly owns 130,376 shares of the company’s common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

CYPHERPUNK TECHNOLOGIES INC. director Christopher Mirabelli reported an open-market sale of 60,000 shares of Common Stock at an average price of $0.7105 per share on March 26, 2026. According to the footnote, the sale was made to cover estimated taxes related to a previously reported settlement of RSUs on March 13, 2026. After this transaction, Mirabelli directly owns 130,376 shares of the company’s common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Cypherpunk Technologies Inc. director Dietz Thomas John exercised previously granted equity awards and increased his direct common share holdings. On March 13, 2026, 104,500 Restricted Stock Units granted on December 23, 2025 under the 2025 Equity Incentive Plan were settled on a 1-for-1 basis into 104,500 shares of common stock for no cash consideration. These RSUs had vested at issuance. Following the settlement, he directly holds 152,500 shares of Cypherpunk Technologies common stock and no remaining RSU position from this grant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. director Dietz Thomas John exercised previously granted equity awards and increased his direct common share holdings. On March 13, 2026, 104,500 Restricted Stock Units granted on December 23, 2025 under the 2025 Equity Incentive Plan were settled on a 1-for-1 basis into 104,500 shares of common stock for no cash consideration. These RSUs had vested at issuance. Following the settlement, he directly holds 152,500 shares of Cypherpunk Technologies common stock and no remaining RSU position from this grant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. director Christopher Mirabelli exercised restricted stock units into common shares as part of his equity compensation. On March 13, 2026, he settled 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 on a 1-for-1 basis into common stock at $0.00 per share. Both RSU grants had vested at issuance. Following these conversions, he directly holds 190,376 shares of common stock and has no remaining derivative positions from these RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Cypherpunk Technologies Inc. director Christopher Mirabelli exercised restricted stock units into common shares as part of his equity compensation. On March 13, 2026, he settled 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 on a 1-for-1 basis into common stock at $0.00 per share. Both RSU grants had vested at issuance. Following these conversions, he directly holds 190,376 shares of common stock and has no remaining derivative positions from these RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. director Oei Khing Djien increased his direct holdings through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were settled 1-for-1 into common shares for no cash consideration. Both RSU grants had vested at issuance. Following these derivative exercises/conversions, he directly holds 168,750 shares of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. director Oei Khing Djien increased his direct holdings through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were settled 1-for-1 into common shares for no cash consideration. Both RSU grants had vested at issuance. Following these derivative exercises/conversions, he directly holds 168,750 shares of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Cypherpunk Technologies Inc. director William Li acquired shares through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were settled on a 1-for-1 basis into common stock for no cash consideration.

These RSUs vested at issuance on their grant dates and were granted under the company’s 2022 and 2025 equity incentive plans. Following the settlements, Li directly holds 168,750 shares of common stock, and no RSU derivatives from these grants remain outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. director William Li acquired shares through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were settled on a 1-for-1 basis into common stock for no cash consideration.

These RSUs vested at issuance on their grant dates and were granted under the company’s 2022 and 2025 equity incentive plans. Following the settlements, Li directly holds 168,750 shares of common stock, and no RSU derivatives from these grants remain outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many Leap Therapeutic (LPTX) SEC filings are available on StockTitan?

StockTitan tracks 68 SEC filings for Leap Therapeutic (LPTX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Leap Therapeutic (LPTX)?

The most recent SEC filing for Leap Therapeutic (LPTX) was filed on May 26, 2026.